---
title: "Distinct Maturation-Associated Neutrophil Transcriptional Programs in COVID-19 Versus Tuberculosis"
id: "biorxiv-2-covid-19-and-active-tuberculosis-exhibit-distinct-maturation-associated"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-2-covid-19-and-active-tuberculosis-exhibit-distinct-maturation-associated"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1?rss=1"
published_at: "2026-11-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Distinct Maturation-Associated Neutrophil Transcriptional Programs in COVID-19 Versus Tuberculosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-2-covid-19-and-active-tuberculosis-exhibit-distinct-maturation-associated
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1?rss=1)
- **Published At:** 2026-11-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators integrated six publicly available whole-blood bulk RNA-sequencing datasets: three cohorts with **COVID-19** and three with active **tuberculosis**. The study used a curated 770-gene panel focused on activation, degranulation, chemotaxis, NET formation, receptors, and maturation. - Study-associated batch variation was reduced using ComBat-Seq; differential expression relative to disease-appropriate controls was analyzed with DESeq2. These preprocessing steps aimed to harmonize multi-cohort data before comparison. - Most genes changed in the same direction in both diseases, but 348 genes (45.2%) exhibited significantly different magnitudes of response between the two infections. Of these, 159 genes had stronger responses in **COVID-19** and 189 in TB. - **COVID-19** samples showed lower expression of maturation markers CD10 (MME) and CD16 (FCGR3A), and higher expression of granule-cargo and NET-associated genes such as MPO and ELANE, consistent with a contribution from immature, emergency granulopoiesis-derived neutrophils. - TB samples exhibited higher expression of maturation-associated genes, receptor transcripts, oxidative pathways, and recruitment signals, consistent with a relatively mature, receptor-competent neutrophil transcriptional signature. - Independent cohorts (a COVID-19 Ward cohort and a pulmonary TB cohort) reproduced maturation and NET-associated signatures with directional agreement of 100% and 90%, respectively; chemotaxis and some receptor/degranulation genes were less reproducible across cohorts. - The authors propose that maturation-associated transcriptional states represent the most consistently reproduced axis distinguishing **neutrophil** programs in **COVID-19** versus TB, offering candidate biomarkers for studies that link neutrophil states to clinical outcomes and to inform host-directed therapies.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=PIvR3Rcz.HE1MBhtm2ttLwz4RSsHVYRj1Un6eAixc9o-1794610596.1292555-1.2.1.1-Yg6mMPkr73xnukQSdPZq2DS51tCzQEjibHCF2uzuXvjWZyDb2tDFg5bzEc7Uefqm) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # COVID-19 and Active Tuberculosis Exhibit Distinct Maturation-Associated Neutrophil Transcriptional Programs [ View ORCID Profile](http://orcid.org/0009-0000-9534-9800)Samuel G. Harrington, Apoorv Shanker, [ View ORCID Profile](http://orcid.org/0000-0001-6215-4871)Jessica Z. Kubicek-Sutherland doi: https://doi.org/10.64898/2026.11.11.765861 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Samuel G. Harrington Los Alamos National Laboratory * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Samuel%2B%2BG.%2BHarrington%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Harrington%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ASamuel%2B%2BG.%2BHarrington%2B) * [ORCID record for Samuel G. Harrington](http://orcid.org/0009-0000-9534-9800 "Open in new tab") Apoorv Shanker Los Alamos National Laboratory * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Apoorv%2BShanker%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Shanker%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AApoorv%2BShanker%2B) Jessica Z. Kubicek-Sutherland Los Alamos National Laboratory * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jessica%2B%2BZ.%2BKubicek-Sutherland%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Kubicek-Sutherland%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AJessica%2B%2BZ.%2BKubicek-Sutherland%2B) * [ORCID record for Jessica Z. Kubicek-Sutherland](http://orcid.org/0000-0001-6215-4871 "Open in new tab") * For correspondence: jzk@lanl.gov * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5959787/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5959787/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5959787/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5959787/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Neutrophils can promote pathogen control or drive tissue-damaging inflammation, but the mechanisms that determine these divergent outcomes remain poorly defined. COVID-19 and active tuberculosis (TB) offer a purposeful comparison since both are pulmonary infections with substantial neutrophil involvement, yet differ in pathogen class, inflammatory duration, and the balance between neutrophil-associated host defense and pathology. We therefore tested whether their divergent neutrophil programs align with distinct maturation-associated transcriptional states. We integrated six publicly available whole-blood bulk RNA-sequencing datasets, comprising three COVID-19 and three active TB cohorts. A curated panel of 770 genes covered activation, degranulation, neutrophil extracellular trap (NET) formation, chemotaxis, cell surface receptors, and maturation. Study-associated variation was reduced using ComBat-Seq, and differential expression relative to disease-appropriate controls was assessed with DESeq2. Most genes changed in the same direction in both diseases, but 348 (45.2%) differed significantly in response magnitude, with 159 genes showing a stronger response in COVID-19 and 189 in TB. COVID-19 samples showed reduced expression of the maturation markers CD10 (MME) and CD16 (FCGR3A), alongside elevated expression of granule-cargo and NET-associated genes, including MPO and ELANE, consistent with a greater contribution from immature, emergency granulopoiesis-derived neutrophil populations. In contrast, TB samples showed higher maturation-associated, receptor, oxidative, and recruitment responses, consistent with a relatively mature receptor-competent neutrophil transcriptional signature. Independent COVID-19 Ward and pulmonary TB cohorts showed directional agreement for maturation and NET-associated signatures (100% and 90% concordance, respectively), while chemotaxis and select receptor and degranulation genes showed weaker reproducibility indicating that maturation represents the most consistently reproduced axis of distinction between the two diseases. Together, these findings identify maturation-associated transcription as the most consistently reproduced axis distinguishing COVID-19 from TB. These signatures provide candidate biomarkers for future studies linking neutrophil states to clinical outcomes and informing host-directed therapeutic strategies that preserve antimicrobial function while limiting immunopathology. ### Competing Interest Statement The authors have declared no competing interest. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.09.765257v1 "Multivalent mRNA tuberculosis vaccines protect against mycobacterial infection in zebrafish, mice and guinea pigs")[Next ](https://www.biorxiv.org/content/10.64898/2026.11.11.765807v1 "The infectious unit of influenza A virus is a population of particles, not a single virion, as shown by absolute particle quantification") Posted November 13, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.11.765861v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/13/2026.11.11.765861.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) COVID-19 and Active Tuberculosis Exhibit Distinct Maturation-Associated Neutrophil Transcriptional Programs Samuel G. Harrington, Apoorv Shanker, Jessica Z. Kubicek-Sutherland bioRxiv 2026.11.11.765861; doi: https://doi.org/10.64898/2026.11.11.765861 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765861v1%26text%3DCOVID-19%2520and%2520Active%2520Tuberculosis%2520Exhibit%2520Distinct%2520Maturation-Associated%2520Neutrophil%2520Transcriptional%2520Programs "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765861v1%26t%3DCOVID-19%2520and%2520Active%2520Tuberculosis%2520Exhibit%2520Distinct%2520Maturation-Associated%2520Neutrophil%2520Transcriptional%2520Programs "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765861v1%26title%3DCOVID-19%2520and%2520Active%2520Tuberculosis%2520Exhibit%2520Distinct%2520Maturation-Associated%2520Neutrophil%2520Transcriptional%2520Programs%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765861v1%26title%3DCOVID-19%2520and%2520Active%2520Tuberculosis%2520Exhibit%2520Distinct%2520Maturation-Associated%2520Neutrophil%2520Transcriptional%2520Programs "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.11.11.765861) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.11.11.765861v1&count=horizontal&via=&text=COVID-19%20and%20Active%20Tuberculosis%20Exhibit%20Distinct%20Maturation-Associated%20Neutrophil%20Transcriptional%20Programs&counturl=www.biorxiv.org/content/10.64898/2026.11.11.765861v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.biorxiv.org/content/early/recent) * [Animal Behavior and Cognition](https://www.biorxiv.org/collection/animal-behavior-and-cognition) (8164) * [Biochemistry](https://www.biorxiv.org/collection/biochemistry) (19027) * [Bioengineering](https://www.biorxiv.org/collection/bioengineering) (15171) * [Bioinformatics](https://www.biorxiv.org/collection/bioinformatics) (45975) * [Biophysics](https://www.biorxiv.org/collection/biophysics) (22958) * [Cancer Biology](https://www.biorxiv.org/collection/cancer-biology) (20298) * [Cell Biology](https://www.biorxiv.org/collection/cell-biology) (27561) * [Clinical Trials](https://www.biorxiv.org/collection/clinical-trials) (138) * [Developmental Biology](https://www.biorxiv.org/collection/developmental-biology) (14274) * [Ecology](https://www.biorxiv.org/collection/ecology) (21588) * [Epidemiology](https://www.biorxiv.org/collection/epidemiology) (2067) * [Evolutionary Biology](https://www.biorxiv.org/collection/evolutionary-biology) (25993) * [Genetics](https://www.biorxiv.org/collection/genetics) (16461) * [Genomics](https://www.biorxiv.org/collection/genom
## Related Clinical Research

- [CohortFM: Reconstructing Continuous Molecular Trajectories from Sparse Longitudinal Samples](https://medichelpline.com/clinical-feed/biorxiv-4-from-sparse-visits-to-continuous-molecular-trajectories-with-flow-matching.md)
- [FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know](https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available.md)
- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [Theranostics for Infectious Lung Diseases: Biotechnology and Nanotechnology for Precision Care](https://medichelpline.com/clinical-feed/pubmed-42549821.md) (DOI: 10.1080/14737159.2026.2714060)
- [Burden of RSV Hospitalizations in Brazilian Adults Aged ≥60 Years (2013–2024)](https://medichelpline.com/clinical-feed/pubmed-42758792.md) (DOI: 10.1371/journal.pone.0357303)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.